On December 7, 2021 HiberCell, a clinical-stage biotechnology company developing therapeutics to address therapeutic resistance, cancer relapse and metastasis, reported that it will present new data from the ongoing phase 2 open-label clinical trial evaluating the company’s odetiglucan (Imprime PGG), in combination with Merck’s anti-PD-1 therapy pembrolizumab, in patients with metastatic breast cancer at the 2021 San Antonio Breast Cancer Symposium (SABCS) from December 7-10, 2021 (Press release, HiberCell, DEC 7, 2021, View Source;utm_medium=rss&utm_campaign=hibercell-to-present-new-data-on-odetiglucan-plus-pembrolizumab-in-ongoing-phase-2-metastatic-breast-cancer-trial-at-san-antonio-breast-cancer-symposium [SID1234596551]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Odetiglucan is a Dectin-1, pattern recognition receptor agonist that has been observed to drive a coordinated innate and adaptive anti-cancer immune cell response in metastatic hormone receptor-positive, HER2-negative breast cancers (mBCA). Hibercell’s prior data supports its belief that combining odetiglucan with pembrolizumab will enhance mBCA patient sensitivity to checkpoint inhibitors (CPI) in those patients who have progressed through hormonal therapy with a CDK4/6 inhibitor. The World Health Organization assigned "odetiglucan" as the International Nonproprietary Name (INN) for Imprime PGG as of November 2021.
Odetiglucan plus pembrolizumab has shown encouraging results in preclinical studies and a prior phase 2 clinical trial, called IMPRIME 1. The ongoing phase 2 clinical trial is now recruiting patients at the SUNY Stony Brook Cancer Center, while actively opening additional clinical trial sites in the U.S.
Presentation number: OT1-18-05
Title: A Multicenter, Open-label, Phase 2 Study of Imprime PGG and Pembrolizumab in Patients with Metastatic Breast Cancer (mBCA) Who Have Progressed Through Prior Hormonal Therapy
Presenter: Alison Stopek, M.D., Stony Brook Cancer Center
Time/Date: Wednesday, December 8, 2021: 5:00 pm – 6:30 pm CT
For more information about HiberCell’s clinical trials, visit the website at www.HiberCell.com.